Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2024-09-16 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed pursuant to the Securities Exchange Act of 1934. It is a regulatory filing used to report material information that is not required to be filed on Form 20-F or 40-F. The content mentions initiation of compliance with HIPAA regulations but does not contain financial statements or detailed financial analysis. The document length is short (1433 characters), and it serves as an announcement/report of a regulatory nature rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS).
2024-09-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NeuroSense Therapeutics Ltd., with the SEC. It reports the completion of a non-rodent toxicity study related to a drug candidate, which is a regulatory update rather than a full financial report. The document is short (2100 characters) and serves as a report of current events or operational updates rather than containing comprehensive financial data or detailed management discussion. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they provide miscellaneous updates from foreign private issuers that do not fit into other specific categories like Annual Reports or Earnings Releases. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about receiving a Nasdaq Minimum Bid Price Notification. The document is short (2161 characters) and primarily serves to furnish a press release rather than containing detailed financial data or comprehensive reports. It does not contain financial statements or detailed analysis, nor is it an annual or quarterly report. The document is an announcement of a regulatory or compliance event related to stock listing requirements. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-08-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NeuroSense Therapeutics Ltd., reporting ongoing advanced discussions for a potential strategic partnership related to its drug candidate. It is a current report pursuant to the Securities Exchange Act of 1934, specifically a Form 6-K, which is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The content focuses on business updates and forward-looking statements about potential agreements and clinical trial progress, without containing detailed financial statements or comprehensive financial analysis. The document length is about 5407 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. It does not contain quarterly or annual financial results, nor is it an earnings release or management discussion. It is not an announcement of a report publication but a standalone regulatory filing providing material business updates. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-08-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It discusses a Nasdaq compliance issue and an extension granted by the Nasdaq Hearings Panel. The document is relatively short (2630 characters) and primarily serves as a regulatory update rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis. It also includes a signature section, typical for regulatory filings. Given these characteristics, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance updates that do not fit other specific categories.
2024-08-26 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by NeuroSense Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content describes a Capital on Demand™ Sales Agreement for the sale of ordinary shares, including details about the sales agent, terms of the agreement, and related exhibits. There is no financial statement or comprehensive financial report included, but rather an announcement of a financing arrangement. Form 6-K filings typically serve as regulatory filings to disclose material events for foreign issuers. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about capital raising activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6154 characters) supports it being a substantive filing rather than a brief announcement or certification.
2024-08-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.